A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study

Status

Not yet recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502911-12-00

Enrollment

Registered

2026-02-23

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Propionic Acidemia

Brief summary

Incidence and severity of AEs (including mRNA-3927 -related and not related AEs), SAEs, and AEs leading to treatment discontinuation.

Detailed description

Annualized frequency of Investigator-reported MDEs., Annualized frequency of Investigator-reported MDE-related hospitalizations., Annualized frequency of Investigator-reported PA-related hospitalizations., Annualized frequency of Investigator-reported PA-related urgent healthcare encounters.

Interventions

DRUGmRNA-3927

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Incidence and severity of AEs (including mRNA-3927 -related and not related AEs), SAEs, and AEs leading to treatment discontinuation.	—

Secondary

Measure	Time frame
Annualized frequency of Investigator-reported MDEs., Annualized frequency of Investigator-reported MDE-related hospitalizations., Annualized frequency of Investigator-reported PA-related hospitalizations., Annualized frequency of Investigator-reported PA-related urgent healthcare encounters.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 25, 2026